Evaluation of human T-cell leukemia virus in vitro diagnostics using plasma specimens collected in Japan
In vitro diagnostics (IVDs) for primary detection test/screening of human T-cell leukemia virus (HTLV) have recently been updated to new-generation products in Japan. In this study, the performance of these products was evaluated and discussed in terms of the usability of HTLV diagnosis in Japan. Th...
Saved in:
Published in | BMC infectious diseases Vol. 23; no. 1; pp. 418 - 8 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
20.06.2023
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | In vitro diagnostics (IVDs) for primary detection test/screening of human T-cell leukemia virus (HTLV) have recently been updated to new-generation products in Japan. In this study, the performance of these products was evaluated and discussed in terms of the usability of HTLV diagnosis in Japan.
The performance of 10 HTLV IVDs for primary detection test and confirmatory/discriminatory test was evaluated. Plasma specimens that had been declared ineligible for transfusion were provided by the Japanese Red Cross Blood Center.
The diagnostic specificity of the IVDs was 100% (160/160). Six sandwich assays resulted in all HTLV-1/HTLV-positive specimens being positive (46/46). On the other hand, one sandwich assay, IVD under development 2 (UD2), resulted in one HTLV-1-positive and one HTLV-positive specimen being negative (44/46, 95.7%). One indirect assay, HISCL HTLV-1, could not detect one HTLV-positive specimen (45/46, 97.8%), but the updated product, UD1, correctly detected it (46/46, 100%). Serodia HTLV-I, based on a particle agglutination assay, resulted in 44 of the 46 positive specimens, but could not detect two specimens (44/46, 95.7%). ESPLINE HTLV-I/II, based on an immunochromatography assay (ICA), was able to diagnose all specimens as positive (46/46, 100%).
Six sandwich assays and an ICA demonstrated high diagnostic sensitivity and specificity and are recommended for use in HTLV diagnosis in conjunction with confirmatory/discriminatory test using the INNO-LIA HTLV-I/II Score. |
---|---|
AbstractList | Abstract Background In vitro diagnostics (IVDs) for primary detection test/screening of human T-cell leukemia virus (HTLV) have recently been updated to new-generation products in Japan. In this study, the performance of these products was evaluated and discussed in terms of the usability of HTLV diagnosis in Japan. Methods The performance of 10 HTLV IVDs for primary detection test and confirmatory/discriminatory test was evaluated. Plasma specimens that had been declared ineligible for transfusion were provided by the Japanese Red Cross Blood Center. Results The diagnostic specificity of the IVDs was 100% (160/160). Six sandwich assays resulted in all HTLV-1/HTLV-positive specimens being positive (46/46). On the other hand, one sandwich assay, IVD under development 2 (UD2), resulted in one HTLV-1-positive and one HTLV-positive specimen being negative (44/46, 95.7%). One indirect assay, HISCL HTLV-1, could not detect one HTLV-positive specimen (45/46, 97.8%), but the updated product, UD1, correctly detected it (46/46, 100%). Serodia HTLV-I, based on a particle agglutination assay, resulted in 44 of the 46 positive specimens, but could not detect two specimens (44/46, 95.7%). ESPLINE HTLV-I/II, based on an immunochromatography assay (ICA), was able to diagnose all specimens as positive (46/46, 100%). Conclusions Six sandwich assays and an ICA demonstrated high diagnostic sensitivity and specificity and are recommended for use in HTLV diagnosis in conjunction with confirmatory/discriminatory test using the INNO-LIA HTLV-I/II Score. In vitro diagnostics (IVDs) for primary detection test/screening of human T-cell leukemia virus (HTLV) have recently been updated to new-generation products in Japan. In this study, the performance of these products was evaluated and discussed in terms of the usability of HTLV diagnosis in Japan. The performance of 10 HTLV IVDs for primary detection test and confirmatory/discriminatory test was evaluated. Plasma specimens that had been declared ineligible for transfusion were provided by the Japanese Red Cross Blood Center. The diagnostic specificity of the IVDs was 100% (160/160). Six sandwich assays resulted in all HTLV-1/HTLV-positive specimens being positive (46/46). On the other hand, one sandwich assay, IVD under development 2 (UD2), resulted in one HTLV-1-positive and one HTLV-positive specimen being negative (44/46, 95.7%). One indirect assay, HISCL HTLV-1, could not detect one HTLV-positive specimen (45/46, 97.8%), but the updated product, UD1, correctly detected it (46/46, 100%). Serodia HTLV-I, based on a particle agglutination assay, resulted in 44 of the 46 positive specimens, but could not detect two specimens (44/46, 95.7%). ESPLINE HTLV-I/II, based on an immunochromatography assay (ICA), was able to diagnose all specimens as positive (46/46, 100%). Six sandwich assays and an ICA demonstrated high diagnostic sensitivity and specificity and are recommended for use in HTLV diagnosis in conjunction with confirmatory/discriminatory test using the INNO-LIA HTLV-I/II Score. Background In vitro diagnostics (IVDs) for primary detection test/screening of human T-cell leukemia virus (HTLV) have recently been updated to new-generation products in Japan. In this study, the performance of these products was evaluated and discussed in terms of the usability of HTLV diagnosis in Japan. Methods The performance of 10 HTLV IVDs for primary detection test and confirmatory/discriminatory test was evaluated. Plasma specimens that had been declared ineligible for transfusion were provided by the Japanese Red Cross Blood Center. Results The diagnostic specificity of the IVDs was 100% (160/160). Six sandwich assays resulted in all HTLV-1/HTLV-positive specimens being positive (46/46). On the other hand, one sandwich assay, IVD under development 2 (UD2), resulted in one HTLV-1-positive and one HTLV-positive specimen being negative (44/46, 95.7%). One indirect assay, HISCL HTLV-1, could not detect one HTLV-positive specimen (45/46, 97.8%), but the updated product, UD1, correctly detected it (46/46, 100%). Serodia HTLV-I, based on a particle agglutination assay, resulted in 44 of the 46 positive specimens, but could not detect two specimens (44/46, 95.7%). ESPLINE HTLV-I/II, based on an immunochromatography assay (ICA), was able to diagnose all specimens as positive (46/46, 100%). Conclusions Six sandwich assays and an ICA demonstrated high diagnostic sensitivity and specificity and are recommended for use in HTLV diagnosis in conjunction with confirmatory/discriminatory test using the INNO-LIA HTLV-I/II Score. Keywords: HTLV IVDs, New generation products, Sensitivity, Specificity In vitro diagnostics (IVDs) for primary detection test/screening of human T-cell leukemia virus (HTLV) have recently been updated to new-generation products in Japan. In this study, the performance of these products was evaluated and discussed in terms of the usability of HTLV diagnosis in Japan. The performance of 10 HTLV IVDs for primary detection test and confirmatory/discriminatory test was evaluated. Plasma specimens that had been declared ineligible for transfusion were provided by the Japanese Red Cross Blood Center. The diagnostic specificity of the IVDs was 100% (160/160). Six sandwich assays resulted in all HTLV-1/HTLV-positive specimens being positive (46/46). On the other hand, one sandwich assay, IVD under development 2 (UD2), resulted in one HTLV-1-positive and one HTLV-positive specimen being negative (44/46, 95.7%). One indirect assay, HISCL HTLV-1, could not detect one HTLV-positive specimen (45/46, 97.8%), but the updated product, UD1, correctly detected it (46/46, 100%). Serodia HTLV-I, based on a particle agglutination assay, resulted in 44 of the 46 positive specimens, but could not detect two specimens (44/46, 95.7%). ESPLINE HTLV-I/II, based on an immunochromatography assay (ICA), was able to diagnose all specimens as positive (46/46, 100%). Six sandwich assays and an ICA demonstrated high diagnostic sensitivity and specificity and are recommended for use in HTLV diagnosis in conjunction with confirmatory/discriminatory test using the INNO-LIA HTLV-I/II Score. In vitro diagnostics (IVDs) for primary detection test/screening of human T-cell leukemia virus (HTLV) have recently been updated to new-generation products in Japan. In this study, the performance of these products was evaluated and discussed in terms of the usability of HTLV diagnosis in Japan.BACKGROUNDIn vitro diagnostics (IVDs) for primary detection test/screening of human T-cell leukemia virus (HTLV) have recently been updated to new-generation products in Japan. In this study, the performance of these products was evaluated and discussed in terms of the usability of HTLV diagnosis in Japan.The performance of 10 HTLV IVDs for primary detection test and confirmatory/discriminatory test was evaluated. Plasma specimens that had been declared ineligible for transfusion were provided by the Japanese Red Cross Blood Center.METHODSThe performance of 10 HTLV IVDs for primary detection test and confirmatory/discriminatory test was evaluated. Plasma specimens that had been declared ineligible for transfusion were provided by the Japanese Red Cross Blood Center.The diagnostic specificity of the IVDs was 100% (160/160). Six sandwich assays resulted in all HTLV-1/HTLV-positive specimens being positive (46/46). On the other hand, one sandwich assay, IVD under development 2 (UD2), resulted in one HTLV-1-positive and one HTLV-positive specimen being negative (44/46, 95.7%). One indirect assay, HISCL HTLV-1, could not detect one HTLV-positive specimen (45/46, 97.8%), but the updated product, UD1, correctly detected it (46/46, 100%). Serodia HTLV-I, based on a particle agglutination assay, resulted in 44 of the 46 positive specimens, but could not detect two specimens (44/46, 95.7%). ESPLINE HTLV-I/II, based on an immunochromatography assay (ICA), was able to diagnose all specimens as positive (46/46, 100%).RESULTSThe diagnostic specificity of the IVDs was 100% (160/160). Six sandwich assays resulted in all HTLV-1/HTLV-positive specimens being positive (46/46). On the other hand, one sandwich assay, IVD under development 2 (UD2), resulted in one HTLV-1-positive and one HTLV-positive specimen being negative (44/46, 95.7%). One indirect assay, HISCL HTLV-1, could not detect one HTLV-positive specimen (45/46, 97.8%), but the updated product, UD1, correctly detected it (46/46, 100%). Serodia HTLV-I, based on a particle agglutination assay, resulted in 44 of the 46 positive specimens, but could not detect two specimens (44/46, 95.7%). ESPLINE HTLV-I/II, based on an immunochromatography assay (ICA), was able to diagnose all specimens as positive (46/46, 100%).Six sandwich assays and an ICA demonstrated high diagnostic sensitivity and specificity and are recommended for use in HTLV diagnosis in conjunction with confirmatory/discriminatory test using the INNO-LIA HTLV-I/II Score.CONCLUSIONSSix sandwich assays and an ICA demonstrated high diagnostic sensitivity and specificity and are recommended for use in HTLV diagnosis in conjunction with confirmatory/discriminatory test using the INNO-LIA HTLV-I/II Score. |
ArticleNumber | 418 |
Audience | Academic |
Author | Hamaguchi, Isao Matsubayashi, Keiji Kusagawa, Shigeru Kawana-Tachikawa, Ai Sobata, Rieko |
Author_xml | – sequence: 1 givenname: Shigeru surname: Kusagawa fullname: Kusagawa, Shigeru – sequence: 2 givenname: Ai surname: Kawana-Tachikawa fullname: Kawana-Tachikawa, Ai – sequence: 3 givenname: Keiji surname: Matsubayashi fullname: Matsubayashi, Keiji – sequence: 4 givenname: Rieko surname: Sobata fullname: Sobata, Rieko – sequence: 5 givenname: Isao surname: Hamaguchi fullname: Hamaguchi, Isao |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37340346$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkl1rFDEUhgep2A_9A15IwJt6MTXfyV5JKbWuFAq6eBvOZpLZ1Jlkncxs9d83262lC15ILhKS5zwcTt7j6iCm6KrqLcFnhGj5MROq1azGlNVYc0zruxfVEeGK1JQxfvDsfFgd53yLMVGazl5Vh0wxjhmXR9XqcgPdBGNIESWPVlMPES1q67oOdW766foAaBOGKaMQy2EcEmoCtDHlMdiMphxii9Yd5B5QXjsbehczsqnrnB1ds636CmuIr6uXHrrs3jzuJ9Xi8-Xi4kt9fXM1vzi_rq0QYqy10Eo1zmo-c1546iSRjfdScezFcimptIop6QFrhzktT4o1TBOsABQIdlLNd9omwa1ZD6GH4Y9JEMzDRRpaA0PpvHNGCUUJpgLEjHOxrS8qi8HRGXDQpLg-7Vzradm7xro4DtDtSfdfYliZNm1MsWpGNCuG00fDkH5NLo-mD3k7W4guTdlQXUDJFMYFfb9DWyi9hehTUdotbs6VYFphKXWhzv5BldWUj7IlHj6U-72CD3sFhRnd77GFKWcz__7t_9mbH_vsu-ezeRrK32QVgO4AO6ScB-efEILNNr5mF19T4mse4mvu2D1Kc-BV |
Cites_doi | 10.1186/s12977-020-00534-0 10.1128/JCM.00169-17 10.1128/CVI.00053-16 10.1016/s0140-6736(86)91298-5 10.1128/JCM.01384-19 10.7754/Clin.Lab.2016.160501 10.1128/JCM.01628-15 10.1002/jcla.22909 10.1097/COH.0b013e3283506613 10.1016/s1473-3099(16)30252-3 10.3389/fmicb.2012.00388 10.1016/j.antiviral.2016.10.015 10.1016/j.diagmicrobio.2009.12.021 10.3389/fmicb.2020.01151 10.1002/jmv.21083 10.1073/pnas.79.6.2031 10.1128/JCM.00659-17 10.1002/jmv.21867 10.1186/s12879-020-05282-2 10.1007/s12185-011-0934-4 10.1128/JCM.37.5.1324-1328.1999 |
ContentType | Journal Article |
Copyright | 2023. The Author(s). COPYRIGHT 2023 BioMed Central Ltd. The Author(s) 2023 |
Copyright_xml | – notice: 2023. The Author(s). – notice: COPYRIGHT 2023 BioMed Central Ltd. – notice: The Author(s) 2023 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 7X8 5PM DOA |
DOI | 10.1186/s12879-023-08402-w |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1471-2334 |
EndPage | 8 |
ExternalDocumentID | oai_doaj_org_article_75721025a594457aa773dc0ae29a4a81 PMC10283183 A753870668 37340346 10_1186_s12879_023_08402_w |
Genre | Journal Article |
GeographicLocations | Japan |
GeographicLocations_xml | – name: Japan |
GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8C1 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR IOV ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM PMFND 7X8 PPXIY 5PM PJZUB PUEGO |
ID | FETCH-LOGICAL-c555t-85877dec849ef5f2e616dff6740f5bb626c7376fa08e042dff73d38107aa7a53 |
IEDL.DBID | M48 |
ISSN | 1471-2334 |
IngestDate | Wed Aug 27 01:15:28 EDT 2025 Thu Aug 21 18:36:52 EDT 2025 Fri Jul 11 05:45:06 EDT 2025 Tue Jun 17 20:48:33 EDT 2025 Tue Jun 10 20:13:59 EDT 2025 Fri Jun 27 05:43:56 EDT 2025 Fri Jun 27 05:53:52 EDT 2025 Thu Jan 02 22:52:21 EST 2025 Tue Jul 01 03:10:43 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Sensitivity Specificity New generation products HTLV IVDs |
Language | English |
License | 2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c555t-85877dec849ef5f2e616dff6740f5bb626c7376fa08e042dff73d38107aa7a53 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12879-023-08402-w |
PMID | 37340346 |
PQID | 2828363700 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_75721025a594457aa773dc0ae29a4a81 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10283183 proquest_miscellaneous_2828363700 gale_infotracmisc_A753870668 gale_infotracacademiconefile_A753870668 gale_incontextgauss_ISR_A753870668 gale_incontextgauss_IOV_A753870668 pubmed_primary_37340346 crossref_primary_10_1186_s12879_023_08402_w |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-06-20 |
PublicationDateYYYYMMDD | 2023-06-20 |
PublicationDate_xml | – month: 06 year: 2023 text: 2023-06-20 day: 20 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | BMC infectious diseases |
PublicationTitleAlternate | BMC Infect Dis |
PublicationYear | 2023 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | M Kuramitsu (8402_CR9) 2017; 55 M Kuramitsu (8402_CR8) 2015; 53 TS Alexander (8402_CR11) 2016; 23 K Umeki (8402_CR20) 2017; 63 K Okuma (8402_CR7) 2020; 17 S Laperche (8402_CR16) 2017; 55 H Ji (8402_CR18) 2020; 11 M Satake (8402_CR5) 2012; 84 J Zhao (8402_CR17) 2020; 20 SM Owen (8402_CR10) 2012; 7 K Malm (8402_CR13) 2010; 82 EC Sabino (8402_CR19) 1999; 37 L Willems (8402_CR4) 2017; 137 A Gessain (8402_CR3) 2012; 3 HP Kapprell (8402_CR12) 2010; 67 M Yoshida (8402_CR1) 1982; 79 8402_CR15 M Satake (8402_CR6) 2016; 16 KR Campos (8402_CR21) 2019; 58 M Osame (8402_CR2) 1986; 1 X Qiu (8402_CR14) 2008; 80 |
References_xml | – volume: 17 start-page: 26 issue: 1 year: 2020 ident: 8402_CR7 publication-title: Retrovirology doi: 10.1186/s12977-020-00534-0 – volume: 55 start-page: 2180 issue: 7 year: 2017 ident: 8402_CR16 publication-title: J Clin Microbiol doi: 10.1128/JCM.00169-17 – volume: 23 start-page: 249 issue: 4 year: 2016 ident: 8402_CR11 publication-title: Clin Vaccine Immunol doi: 10.1128/CVI.00053-16 – volume: 1 start-page: 1031 issue: 8488 year: 1986 ident: 8402_CR2 publication-title: Lancet doi: 10.1016/s0140-6736(86)91298-5 – volume: 58 start-page: e01384 issue: 1 year: 2019 ident: 8402_CR21 publication-title: J Clin Microbiol doi: 10.1128/JCM.01384-19 – volume: 63 start-page: 227 issue: 2 year: 2017 ident: 8402_CR20 publication-title: Clin Lab doi: 10.7754/Clin.Lab.2016.160501 – volume: 53 start-page: 3485 issue: 11 year: 2015 ident: 8402_CR8 publication-title: J Clin Microbiol doi: 10.1128/JCM.01628-15 – ident: 8402_CR15 doi: 10.1002/jcla.22909 – volume: 7 start-page: 125 issue: 2 year: 2012 ident: 8402_CR10 publication-title: Curr Opin HIV AIDS doi: 10.1097/COH.0b013e3283506613 – volume: 16 start-page: 1246 year: 2016 ident: 8402_CR6 publication-title: Lancet Infect Dis doi: 10.1016/s1473-3099(16)30252-3 – volume: 3 start-page: 388 year: 2012 ident: 8402_CR3 publication-title: Front Microbiol doi: 10.3389/fmicb.2012.00388 – volume: 137 start-page: 41 year: 2017 ident: 8402_CR4 publication-title: Antiviral Res doi: 10.1016/j.antiviral.2016.10.015 – volume: 67 start-page: 61 issue: 1 year: 2010 ident: 8402_CR12 publication-title: Diagn Microbiol Infect Dis doi: 10.1016/j.diagmicrobio.2009.12.021 – volume: 11 start-page: 1151 year: 2020 ident: 8402_CR18 publication-title: Front Microbiol doi: 10.3389/fmicb.2020.01151 – volume: 80 start-page: 484 issue: 3 year: 2008 ident: 8402_CR14 publication-title: J Med Virol doi: 10.1002/jmv.21083 – volume: 79 start-page: 2031 issue: 6 year: 1982 ident: 8402_CR1 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.79.6.2031 – volume: 55 start-page: 2838 issue: 9 year: 2017 ident: 8402_CR9 publication-title: J Clin Microbiol doi: 10.1128/JCM.00659-17 – volume: 82 start-page: 1606 issue: 9 year: 2010 ident: 8402_CR13 publication-title: J Med Virol doi: 10.1002/jmv.21867 – volume: 20 start-page: 581 issue: 1 year: 2020 ident: 8402_CR17 publication-title: BMC Infect Dis doi: 10.1186/s12879-020-05282-2 – volume: 84 start-page: 327 year: 2012 ident: 8402_CR5 publication-title: J Med Virol doi: 10.1007/s12185-011-0934-4 – volume: 37 start-page: 1324 issue: 5 year: 1999 ident: 8402_CR19 publication-title: J Clin Microbiol doi: 10.1128/JCM.37.5.1324-1328.1999 |
SSID | ssj0017829 |
Score | 2.3694618 |
Snippet | In vitro diagnostics (IVDs) for primary detection test/screening of human T-cell leukemia virus (HTLV) have recently been updated to new-generation products in... Background In vitro diagnostics (IVDs) for primary detection test/screening of human T-cell leukemia virus (HTLV) have recently been updated to new-generation... Abstract Background In vitro diagnostics (IVDs) for primary detection test/screening of human T-cell leukemia virus (HTLV) have recently been updated to... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 418 |
SubjectTerms | Algorithms Analysis Blood banks Breast feeding Care and treatment Diagnosis Diagnostic reagents Health aspects HTLV IVDs HTLV-I Infections - diagnosis Human T-lymphotropic virus 1 Human T-lymphotropic virus 2 Humans Japan Leukemia Leukemia, T-Cell Maternal-fetal exchange New generation products Sensitivity Specificity T cells |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k3agtwKiQOKmo2fORbUqlQqSLCg3izHsdsVNKk2G_r3mXGyq7UQ4sItiidRPDOeRzzzmZA3Iqg6COdy8JUu57Ks8rridT5zzAutnZ9FnO2LT_LsGz-_FJdbR31hTdgIDzwy7kgJhVmJsKLiXChrlWKNK6wvK8ttbLouweetk6lp_wD8XrVukdHyqAcrrKoc_BPimIINuEvcUETr_9MmbzmltGByywOdPiIPp9CRHo-f_Jjc8-0Tcv9i2hx_Sq5PNsjdtAs0nr5H5zn-mqc__fDD3yws_bVYDj1dtHCxWna0GSvtEKuZYgn8Fb2FcPrGUuzAROD_nqKmgFX0DT51Dr61fUbmpyfzD2f5dJBC7oQQq1wLrVTjneaVDyKUXs5kE4JUvAiiriGncQoMTbCF9rCIYQh4jNBfyG4r2HOy03atf0looUPhmtDwGoHiuLQQHkrG4UWqbmaVzci7NVvN7QiXYWKaoaUZhWBACCYKwdxl5D1yfkOJUNfxBiiAmRTA_EsBMnKIcjMIZtFitcyVHfrefPz83RxDLob7uFL_jejrl4To7UQUOhCzs1OHAkwdQbISyv2EEpakS4YP1jpkcAjr2FrfDb3BBJdJpooiIy9GndrMninGC8ZlRnSibQl70pF2cR0RwWOUCMZ5938wdI88KONKkWBC98nOajn4VxB5rerXcZH9BocnKWc priority: 102 providerName: Directory of Open Access Journals |
Title | Evaluation of human T-cell leukemia virus in vitro diagnostics using plasma specimens collected in Japan |
URI | https://www.ncbi.nlm.nih.gov/pubmed/37340346 https://www.proquest.com/docview/2828363700 https://pubmed.ncbi.nlm.nih.gov/PMC10283183 https://doaj.org/article/75721025a594457aa773dc0ae29a4a81 |
Volume | 23 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZ2kaa9IO4rjMogJB5QIGl8ywNC69RpTOpApUMTL5bj2F3Flo6mZfDvOcdNSyPGCy9RVB9Xic89Pv4OIS-5l7nn1kbgK23ERCeL8ozlUWJTx5WyLgk42_1TcXzGTs75-QZZtjuqF7C6NbXDflJn08s3P7__eg8K_y4ovBJvK7CxMovA-yBKKWj4zSbZBs8ksaNBn_3ZVQBvmC0Pztw6b5fspDJlcYrx8JqfCnD-fxvtNa_VrKhcc1FHd8mdOrakBwthuEc2XHmf7PTr3fMH5KK3gvamE09Dez46jPDbPb1082_uamzoj_F0XtFxCTez6YQWi1I8BHOmWCM_otcQb18Zikc0sTNARVGUwGy6AmedgPMtH5LhUW94eBzVnRYiyzmfRYorKQtnFcuc577jRCIK74Vksed5DkmPlWCJvImVAy2HIZkWiA0mjZGGp4_IVjkp3R6hsfKxLXzBckSSY8JA_ChSBn8k8yLJTIu8Xi6rvl7gaeiQhyihF_zQwA8d-KFvWqSLK7-iRCzs8MNkOtK1amnJJeat3PCMMY5PBA9nY-M6mWFGJS3yAvmmEe2ixHKakZlXlf7w8Ys-gGQNN3qF-hfR50GD6FVN5CfAZmvqIwzw6oii1aDcb1CCztrG8POlDGkcwkK30k3mlcYMOBWpjOMWebyQqdXbL0WzRVRD2hrL0xwpxxcBMjyEkWC9n_z_1KdktxNURYBl3Sdbs-ncPYOAbJa3yaY8l3BVh0mbbHd7p58G7fBxox30D66D7tffXoQ4Pw |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+human+T-cell+leukemia+virus+in+vitro+diagnostics+using+plasma+specimens+collected+in+Japan&rft.jtitle=BMC+infectious+diseases&rft.au=Kusagawa%2C+Shigeru&rft.au=Kawana-Tachikawa%2C+Ai&rft.au=Matsubayashi%2C+Keiji&rft.au=Sobata%2C+Rieko&rft.date=2023-06-20&rft.pub=BioMed+Central&rft.eissn=1471-2334&rft.volume=23&rft_id=info:doi/10.1186%2Fs12879-023-08402-w&rft_id=info%3Apmid%2F37340346&rft.externalDocID=PMC10283183 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2334&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2334&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2334&client=summon |